Survival Improvement in Korean Breast Cancer Patients Due to Increases in Early-Stage Cancers and Hormone Receptor Positive/HER2 Negative Subtypes: A Nationwide Registry-Based Study

You, Jee Man; Kim, Yun Gyoung; Moon, Hyeong‐Gon; Nam, Seok Jin; Lee, Jong Won; Lim, Woosung; Lee, Mi Ri; Noh, Dong Young; Han, Wonshik

doi:10.4048/jbc.2015.18.1.8

Cited by 12 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Korea has one of the lowest breast cancer incidence rates (50.7 per 100,000 women-years in 2012) [ 3 4 5 ]; however, this incidence is rising rapidly, and breast cancer is now the second-most common cancer among women in Korea [ 3 6 7 ]. However, like many other developed countries, the age-adjusted death rate in Korean patients with breast cancer has been decreasing [ 8 ]. Many reports have provided possible relevant explanations for the recent improvement in survival in patients with breast cancer.…”

Section: Introductionmentioning

confidence: 99%

“…Many reports have provided possible relevant explanations for the recent improvement in survival in patients with breast cancer. These explanations include nationwide screening programs with improved early detection of breast cancer [ 9 ], increases in the proportion of less aggressive cancers [ 8 ], and advances in adjuvant treatment, such as aromatase inhibitors for hormone receptor-positive tumors and trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive tumors [ 10 11 12 ]. However, almost all of these studies have been from Western countries, and there are limited data to explain the improved breast cancer survival outcomes in Korea.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study

et al. 2018

Self Cite

View full text Add to dashboard Cite

PurposeThis study aimed to chronologically evaluate survival of patients with breast cancer in Korea and investigate the observed changes during the last 20 years. We also sought to determine factors that may influence outcomes and changes in the duration of survival over time.MethodsWe retrospectively analyzed a total of 10,988 patients with breast cancer who were treated at our institution between January 1993 and December 2008. We divided the study period into three periods (P1, 1993–1997; P2, 1998–2002; and P3, 2003–2008). We retrospectively reviewed the collected data from the Asan database, including age at diagnosis, clinical manifestations, pathology report, surgical methods, types of adjuvant treatment modalities, type of recurrence, and follow-up period.ResultsAt a median follow-up of 8.2 years, we observed that survival outcomes have improved recently. The 5-year breast cancer-specific survival (BCSS) rate also increased from 82.8% in P1 to 92.6% in P3 (p<0.001). The survival rate in patients with tumors at each stage increased in similar patterns in all patients, and, remarkably, there was a significant survival improvement in patients with stage III breast cancer (P1 vs. P3: 5-year BCSS, 57.4% vs. 80.0%, p<0.001). The time period was a significant prognostic factor in multivariate analysis (P1 vs. P2: hazard ratio [HR], 0.83, p=0.035; P1 vs. P3: HR, 0.75, p=0.015).ConclusionThe study results suggest an improvement in breast cancer survival in Korea, which is consistent with the development of treatments and early detection.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…In most studies, TN and HER2+ tumors showed the poorest survival rates [22,23]. In a study by You et al [1], early-stage tumors without lymph node invasion and with improved histological appearance resulted in better survivals in all molecular subtypes. High-stage disease and HR negativity were associated with poor survival rates.…”

Section: Prognosis Survival and Risk Factors That Affect Themmentioning

confidence: 98%

“…Breast cancer is common among women between the ages of 50 and 60 years and is one of the leading causes of disease-related deaths [1]. There is no single marker that determines the clinical properties and treatment of breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Histopathological Characteristics: Clinical Course of Breast Cancer Subtypes Depending on the ER(+) (−)/PR(+) (−) Receptor Status

Bulut¹

2017

Breast Cancer - From Biology to Medicine

View full text Add to dashboard Cite

Breast cancer patients were divided into separate groups, which were the estrogen receptor ER +/progesterone receptor PR + HER −, the ER or PR+ HER −, the ER+/ PR+ HER +, the ER or PR+ HER +, the ER−/PR− HER −, and the ER−/PR− HER + groups. Patients with the ER/PR + /HER − subtype breast cancers show beter clinical prognosis compared to the hormone-negative, triple-negative TN , and HER + subtypes. TN, HER + tumors in postmenopausal women were of higher grade, showing lymph node and lymphovascular invasion with poor prognosis in all case series. However, the ER+/PR−/HER + subgroup had the lowest survival rates inand -year follow-ups. Comparison between the ER+PR+HER + and ER+PR−HER − subgroups showed that HER − status is an indicator of improved prognosis in longterm follow-up. Single hormone receptor HR + status, particularly HER − cases, was in between the favorable and poor survival subgroups. The ER−, PR−, and HER + properties were found to be risk factors for frequent recurrences. In this chapter, breast cancer subtypes are compared with each other. Results from diferent studies highlight the importance of ER/PR/HER receptor variations in the choice of treatment and prognosis of breast cancer.

show abstract

“…Recent data from the Korean Breast Cancer Registry show that ~75% of women who received surgery for breast cancer had the HER2-negative subtype. 3 …”

Section: Introductionmentioning

confidence: 99%

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea

Tremblay¹,

Majethia²,

Breeze³

et al. 2016

CEOR

View full text Add to dashboard Cite

BackgroundMetastatic breast cancer (MBC) is associated with poor prognosis, particularly for those patients with human epidermal growth factor receptor (HER2)-negative tumor. Similar to the rest of the world, treatment options are limited in South Korea following first-line chemotherapy with anthracyclines and/or taxanes. This study examined the cost-effectiveness and cost-utility of eribulin in South Korean patients with HER2-negative MBC who have progressed after usage of at least one chemotherapeutic regimen for advanced disease (second-line therapy).MethodsA partition survival model was developed from the perspective of the South Korean health care system. The economic impact of introducing eribulin as second-line therapy for HER2-negative MBC was compared to that of capecitabine and vinorelbine. The analysis estimated incremental cost per life-year (LY), that is, cost-effectiveness, and cost per quality-adjusted life-year (QALY), that is, cost-utility, of eribulin for management of HER2-negative MBC in South Korea. The model accounted for overall survival, progression-free survival, drug costs, grade 3/4 adverse events, and health care utilization. Deterministic and probabilistic sensitivity analyses were performed to identify uncertainty in the results of the economic evaluation.ResultsSecond-line eribulin was associated with greater benefits in terms of LY and QALY, compared to capecitabine and vinorelbine. The incremental cost-effectiveness ratio was ₩10.5M (approximately USD 9,200) per LY, and the incremental cost-utility ratio was ₩17M (approximately USD 14,800) per QALY in the basecase analysis. The incremental cost-utility ratio ranged from ₩12M (USD 10,461) to ₩27M (USD 23,538) per QALY in the deterministic sensitivity analysis. In the probabilistic sensitivity analysis, >99% of the simulations were below ₩50M (USD 42,300), and the lower and upper 95% confidence intervals were ₩3M (USD 2,600) and ₩24M (USD 20,900) per QALY, respectively.ConclusionThere currently exist a limited number of treatment choices for women with HER2-negative MBC. Eribulin is a cost-effective option for second-line therapy in South Korea and should be added to the current indications for reimbursement.

show abstract

Survival Improvement in Korean Breast Cancer Patients Due to Increases in Early-Stage Cancers and Hormone Receptor Positive/HER2 Negative Subtypes: A Nationwide Registry-Based Study

Cited by 12 publications

References 16 publications

Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study

Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study

Histopathological Characteristics: Clinical Course of Breast Cancer Subtypes Depending on the ER(+) (−)/PR(+) (−) Receptor Status

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea

Contact Info

Product

Resources

About